Is Cortisol Inhibition the key to treating Alzheimer’s Disease?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Is Cortisol Inhibition the key to treating Alzheimer’s Disease?
Released on: January 12, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Bill Ketelbey, CEO and Managing Director of Actinogen, discusses the development of their lead compound XanamemTM , currently in clinical trials for the treatment of neurodegenerative diseases.
  • Summary
  • Transcript
  • Participants
  • Company
Bill Ketelbey, CEO and Managing Director of Actinogen, discusses the development of their lead compound XanamemTM , currently in clinical trials for the treatment of neurodegenerative diseases.
Bill Ketelbey, CEO and Managing Director of Actinogen, discusses the development of their lead compound XanamemTM , currently in clinical trials for the treatment of neurodegenerative diseases.
Dr Bill Ketelbey is a highly experienced and successful healthcare and pharmaceutical sector professional, with 30 years’ experience in the industry, including most recently in senior medical and management roles with global pharmaceutical giant, Pfizer. Prior to joining Actinogen Medical, Dr Ketelbey was Regional Vice President of Medical Affairs for Pfizer’s Primary Care Business Unit for Australia and New Zealand, Japan, Canada, Korea and Country Medical Director for Pfizer Australia and New Zealand. Dr Ketelbey has a solid track record of product development over his years in the industry leading to the successful registration, launch and commercialisation of numerous market leading medicines in a broad range of therapeutic areas, including in Alzheimer’s Disease. At Pfizer, Dr Ketelbey led the Australian/New Zealand clinical development, and was involved in the launch and commercialisation of Aricept™ (donepezil), an acetylcholinesterase inhibitor, the market leading Alzheimer’s disease therapy locally and globally. More recently he was involved in developing monoclonal antibodies directed at amyloid plaques, a hallmark of Alzheimer’s. Dr Ketelbey is a medical graduate from the University of the Witwatersrand, South Africa, a Fellow of the Faculty of Pharmaceutical Physicians from the Royal College of Physicians in the UK, has an MBA from Macquarie Graduate School of Management, Australia and is a Graduate of the Australian Institute of Company Directors
Actinogen Medical is focused on the treatment of Alzheimer’s Disease and mild cognitive impairment, a transitional stage of cognitive impairment between normal aging and the more serious conditions of Alzheimer’s and dementia. It is developing a novel drug to treat the condition and other age-related neurodegenerative diseases. The lead candidate drug Xanamem™, blocks the development of cortisol which appears to contribute to cognitive impairment and neurological plaques. The company is currently undertaking a second Phase I multiple ascending dose trial in humans with results in mid-2015 and plans to undertake a Phase II study in late 2015. Actinogen was previously focused on antimicrobial and anti-cancer early stage drug discovery.